0

Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936-1974

Resseguie LJ et al., 1985

Fertility and sterility, 43(4), 514-519

DOI 10.1016/s0015-0282(16)48490-6 PMID 3987922 Source

Abstract

Comparison of a cohort of 988 offspring exposed in utero to exogenous progestins with a matched cohort of unexposed offspring did not result in detection of an association of congenital anomalies with exposure. The conclusions are based primarily on outcomes of pregnancy with exposure to progesterone and 17 alpha-hydroxyprogesterone caproate, and may not apply to androgenic progestins. Offspring exposed to combinations of progestins and estrogens were excluded from this study and may have a different distribution of anomalies.

Topics

Reproductive Endocrinology > Progesterone > SupplementationPregnancy > Outcomes > Complications
progesterone safety pregnancy, progestin birth defects risk, congenital anomalies hormone exposure, 17-hydroxyprogesterone caproate safety, in utero progestin exposure outcomes, pregnancy progesterone teratogenic effects, synthetic progestin fetal development, progesterone supplementation safety data, hydroxyprogesterone pregnancy complications, hormone therapy pregnancy malformations, cohort study progestin exposure, prenatal hormone exposure outcomes

Cite this article

Resseguie, L. J., Hick, J. F., Bruen, J. A., Noller, K. L., O'Fallon, W. M., & Kurland, L. T. (1985). Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936-1974. *Fertility and sterility*, *43*(4), 514-519. https://doi.org/10.1016/s0015-0282(16)48490-6

Keywords

17 alpha-Hydroxyprogesterone Caproate, Abnormalities, Drug-Induced, Ethisterone, Female, Fetal Death, Humans, Hydroxyprogesterones, Infant, Newborn, Male, Maternal-Fetal Exchange, Medroxyprogesterone, Minnesota, Norethindrone, Pregnancy, Prenatal Exposure Delayed Effects, Progesterone, Progestins

Related articles